Targeting calcitonin gene-related peptide: a new era in migraine therapy

[1]  R. Lipton,et al.  Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial , 2019, The Lancet.

[2]  R. Lipton,et al.  Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. , 2019, The New England journal of medicine.

[3]  R. Lipton,et al.  Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial , 2019, Cephalalgia : an international journal of headache.

[4]  P. Pozo‐Rosich,et al.  How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective , 2019, Current opinion in neurology.

[5]  S. Silberstein,et al.  Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine , 2019, Cephalalgia : an international journal of headache.

[6]  S. Sacco,et al.  Correction to: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention , 2019, The Journal of Headache and Pain.

[7]  S. Aurora,et al.  Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure , 2019, Cephalalgia : an international journal of headache.

[8]  D. Dodick,et al.  Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[9]  H. Diener,et al.  Erenumab in chronic migraine with medication overuse , 2019, Neurology.

[10]  R. Lipton,et al.  Erenumab in chronic migraine , 2019, Neurology.

[11]  L. Edvinsson,et al.  Distribution of CGRP and CGRP receptor components in the rat brain , 2019, Cephalalgia : an international journal of headache.

[12]  The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice , 2018, Headache.

[13]  S. Aurora,et al.  Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies , 2018, The Journal of Headache and Pain.

[14]  S. Silberstein,et al.  The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post‐Hoc Analyses on the First 3 Weeks of Treatment , 2018, Headache.

[15]  S. Aurora,et al.  Galcanezumab in chronic migraine , 2018, Neurology.

[16]  D. Kudrow,et al.  A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine , 2018, BMC Neurology.

[17]  M. Ferrari,et al.  Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study , 2018, The Lancet.

[18]  Ivy Shiue,et al.  Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet Neurology.

[19]  M. Ashina,et al.  Effect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks: A Randomized Clinical Trial , 2018, JAMA neurology.

[20]  E. Pearlman,et al.  100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies , 2018, Headache.

[21]  M. Ashina,et al.  Early onset of efficacy with erenumab in patients with episodic and chronic migraine , 2018, The Journal of Headache and Pain.

[22]  R. Conley,et al.  Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial , 2018, JAMA neurology.

[23]  R. Lipton,et al.  Fremanezumab for preventive treatment of migraine , 2018, Neurology.

[24]  R. Lipton,et al.  Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab , 2018, Cephalalgia : an international journal of headache.

[25]  P. Goadsby,et al.  Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study , 2018, Cephalalgia : an international journal of headache.

[26]  M. Ashina,et al.  Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study , 2018, Cephalalgia : an international journal of headache.

[27]  L. Edvinsson,et al.  CGRP as the target of new migraine therapies — successful translation from bench to clinic , 2018, Nature Reviews Neurology.

[28]  M. Matharu,et al.  Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial , 2018, Cephalalgia : an international journal of headache.

[29]  A. van Hecken,et al.  Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers , 2018, Cephalalgia : an international journal of headache.

[30]  S. Silberstein,et al.  Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial , 2018, JAMA.

[31]  C. Depré,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina , 2018, Headache.

[32]  Edgar Bautista,et al.  Phase I, Randomized, Double‐blind, Placebo‐controlled, Single‐dose, and Multiple‐dose Studies of Erenumab in Healthy Subjects and Patients With Migraine , 2018, Clinical pharmacology and therapeutics.

[33]  P. Loupe,et al.  A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects , 2018, Cephalalgia : an international journal of headache.

[34]  D. Dodick,et al.  ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.

[35]  R. Palmiter,et al.  Encoding of danger by parabrachial CGRP neurons , 2018, Nature.

[36]  M. Hodsdon,et al.  Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study , 2018, Cephalalgia : an international journal of headache.

[37]  Kirk W. Johnson,et al.  Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial , 2017, JAMA neurology.

[38]  P. Goadsby,et al.  A Controlled Trial of Erenumab for Episodic Migraine , 2017, The New England journal of medicine.

[39]  S. Silberstein,et al.  Fremanezumab for the Preventive Treatment of Chronic Migraine , 2017, The New England journal of medicine.

[40]  D. Grayzel,et al.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers , 2017, Front. Pharmacol..

[41]  R. Lipton,et al.  Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design , 2017, The Journal of Headache and Pain.

[42]  D. Dodick,et al.  Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines , 2017, Headache.

[43]  Feng Zhang,et al.  Erenumab (AMG 334) in episodic migraine , 2017, Neurology.

[44]  S. Silberstein,et al.  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial , 2017, The Lancet Neurology.

[45]  D. Dodick,et al.  Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis , 2016, Cephalalgia : an international journal of headache.

[46]  Yufeng Zheng,et al.  Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats , 2016, Nature Medicine.

[47]  Arne May,et al.  The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. , 2016, Brain : a journal of neurology.

[48]  R. Lipton,et al.  A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine , 2016, Cephalalgia : an international journal of headache.

[49]  S. Silberstein,et al.  Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[50]  M. Ferrari,et al.  Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine , 2016, Cephalalgia : an international journal of headache.

[51]  R. Lipton,et al.  Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study , 2015, The Lancet Neurology.

[52]  R. Lipton,et al.  Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study , 2015, The Lancet Neurology.

[53]  J. Olesen,et al.  Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial , 2014, The Lancet Neurology.

[54]  C. Lines,et al.  Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention , 2014, Neurology.

[55]  D. Dodick,et al.  Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study , 2014, The Lancet Neurology.

[56]  D. Dodick,et al.  BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial , 2014, Cephalalgia : an international journal of headache.

[57]  L. Edvinsson,et al.  Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. , 2013, The journal of pain : official journal of the American Pain Society.

[58]  Sandra M. Sanabria-Bohórquez,et al.  In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232 , 2013, The Journal of Pharmacology and Experimental Therapeutics.

[59]  A. Charles.  Vasodilation out of the picture as a cause of migraine headache , 2013, The Lancet Neurology.

[60]  H. Larsson,et al.  Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study , 2013, The Lancet Neurology.

[61]  B. Chaitman,et al.  A Randomized, Placebo‐Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina , 2012, Clinical pharmacology and therapeutics.

[62]  C. Lines,et al.  Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease , 2012, Headache.

[63]  J. Chodakewitz,et al.  Effect of Telcagepant on Spontaneous Ischemia in Cardiovascular Patients in a Randomized Study , 2011, Headache.

[64]  C. Lines,et al.  Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine , 2011, Cephalalgia : an international journal of headache.

[65]  J. Olesen,et al.  Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura , 2010, Cephalalgia : an international journal of headache.

[66]  C. Lines,et al.  Randomized, controlled trial of telcagepant for the acute treatment of migraine , 2009, Neurology.

[67]  David W Dodick,et al.  Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial , 2008, The Lancet.

[68]  J. Cornish,et al.  The role of peptides and receptors of the calcitonin family in the regulation of bone metabolism. , 2008, Bone.

[69]  A. W. Shaw,et al.  Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]-4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). , 2007, Journal of medicinal chemistry.

[70]  H. Diener,et al.  Long‐Term Migraine Prevention With Topiramate: Open‐Label Extension of Pivotal Trials , 2006, Headache.

[71]  J. Olesen,et al.  Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. , 2004, The New England journal of medicine.

[72]  J. Olesen,et al.  Cgrp May Play A Causative Role in Migraine , 2002, Cephalalgia : an international journal of headache.

[73]  P. Goadsby,et al.  Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. , 1994, Brain : a journal of neurology.

[74]  P. Goadsby,et al.  The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats , 1993, Annals of neurology.

[75]  P. Goadsby,et al.  Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides , 1990, Neuropeptides.

[76]  P. Goadsby,et al.  Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system , 1988, Annals of neurology.

[77]  J. Mcculloch,et al.  Calcitonin gene-related peptide: functional role in cerebrovascular regulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[78]  J. Mcculloch,et al.  Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P , 1985, Neuroscience Letters.

[79]  M. Mortrud,et al.  Calcitonin gene related peptide inhibits basal, pentagastrin, histamine, and bethanecol stimulated gastric acid secretion. , 1985, Gut.

[80]  H. Morris,et al.  Calcitonin gene-related peptide is a potent vasodilator , 1985, Nature.

[81]  H. Morris,et al.  The myotropic and plasma-calcium modulating effects of calcitonin gene-related peptide (CGRP) , 1984, Neuropeptides.

[82]  S. Amara,et al.  Stimulation of noradrenergic sympathetic outflow by calcitonin gene-related peptide , 1983, Nature.

[83]  L. Swanson,et al.  Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing , 1983, Nature.

[84]  D. Dodick,et al.  Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials , 2019, Cephalalgia : an international journal of headache.

[85]  L. Edvinsson,et al.  Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography , 2016, The Journal of comparative neurology.

[86]  J. Wilson,et al.  Migraine , 2007, Annals of Internal Medicine.